Business
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene Administration of OPGx-LCA5 by subretinal injection was well tolerated by study participants RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treat
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xl5Pbyep4pXJ5VZR6DH1.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd","width":300,"height":129}},"lazy":false},{"type":"text","content":"Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene","length":229,"tagName":"p"},{"type":"text","content":"Administration of OPGx-LCA5 by subretinal injection was well tolerated by study participants","length":97,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders (“Opus” or the “Company”), today announced one-year results from adult patients treated in the ongoing Phase 1/2 Study of its lead gene therapy candidate OPGx-LCA5. These results were presented yesterday at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), taking place May 4 – 7, 2025 in Salt Lake City, Utah. The presentation, entitled “Recovery of Cone-Mediated Vision in a Severe Ciliopathy after Gene Augmentation: One Year Results of a Phase I/II Trial for LCA5-LCA,” was delivered by Dr. Tomas Aleman of the Scheie Eye Institute, University of Pennsylvania.","length":881,"tagName":"p"},{"type":"text","content":"“The preliminary data emerging from this Phase 1/2 study of OPGx-LCA5 are very encouraging. We are pleased to see evidence of durable efficacy, with the treatment benefits observed at six months being sustained out to one year,” said Dr. Aleman. “Unquestionable gains in cone-mediated vision (daytime) confirmed one year after treatment have been associated with improvements in patients’ reading vision and ability to recognize objects, which are meaningful to thes...